These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam. Dao TV; Nguyen CV; Nguyen QT; Vu HTN; Phung HT; Bui OT; Nguyen DK; Luong BV; Tran TV Cancer Control; 2020; 27(1):1073274820968883. PubMed ID: 33136444 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Ulase D; Heckl S; Behrens HM; Krüger S; Röcken C Histopathology; 2020 Feb; 76(3):433-446. PubMed ID: 31538348 [TBL] [Abstract][Full Text] [Related]
5. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563 [TBL] [Abstract][Full Text] [Related]
6. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M; Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156 [TBL] [Abstract][Full Text] [Related]
7. Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. Dawson H; Galuppini F; Träger P; Berger MD; Studer P; Brügger L; Zlobec I; Inderbitzin D; Lugli A Hum Pathol; 2019 Mar; 85():145-151. PubMed ID: 30428391 [TBL] [Abstract][Full Text] [Related]
8. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090 [TBL] [Abstract][Full Text] [Related]
9. Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer. Zlobec I; Bächli M; Galuppini F; Berger MD; Dawson HE; Nagtegaal ID; Lugli A Virchows Arch; 2021 Dec; 479(6):1085-1090. PubMed ID: 33843013 [TBL] [Abstract][Full Text] [Related]
10. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112 [TBL] [Abstract][Full Text] [Related]
12. Should a fourth category be added to the international tumor budding consensus conference tumor budding scoring system in colorectal adenocarcinomas? Secinti IE; Ozgur T; Gursoy D; Dede I APMIS; 2022 Sep; 130(9):560-567. PubMed ID: 35816469 [TBL] [Abstract][Full Text] [Related]
13. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Karamitopoulou E; Esposito I; Zlobec I; Insilla AC; Wartenberg M; Schaeffer DF; Kalloger S; La Rosa S; Sempoux C; Ramos Centeno I; Lohneis P Virchows Arch; 2021 Apr; 478(4):719-726. PubMed ID: 33330964 [TBL] [Abstract][Full Text] [Related]
14. Reporting of tumor budding in colorectal adenocarcinomas using ×40 objective: A practical approach for resource constrained set-ups. Roy P; Datta J; Roy M; Mallick I; Mohandas M Indian J Cancer; 2017; 54(4):640-645. PubMed ID: 30082550 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of tumour budding in stomach cancers. Kucuk S Int J Clin Pract; 2021 Dec; 75(12):e14922. PubMed ID: 34580963 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive values of tumour budding in stage IV colorectal cancer. Nagata K; Shinto E; Yamadera M; Shiraishi T; Kajiwara Y; Okamoto K; Mochizuki S; Hase K; Kishi Y; Ueno H BJS Open; 2020 Aug; 4(4):693-703. PubMed ID: 32472647 [TBL] [Abstract][Full Text] [Related]
17. Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma. Aherne S; Donnelly M; Ryan ÉJ; Davey MG; Creavin B; McGrath E; McCarthy A; Geraghty R; Gibbons D; Nagtegaal I; Lugli A; Kirsch R; Martin ST; Winter DC; Sheahan K; Histopathology; 2024 Aug; 85(2):224-243. PubMed ID: 38629323 [TBL] [Abstract][Full Text] [Related]
18. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Schlitter AM; Jesinghaus M; Jäger C; Konukiewitz B; Muckenhuber A; Demir IE; Bahra M; Denkert C; Friess H; Kloeppel G; Ceyhan GO; Weichert W Eur J Cancer; 2017 Oct; 84():121-129. PubMed ID: 28802189 [TBL] [Abstract][Full Text] [Related]
19. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. Chen YT; Huang ZP; Zhou ZW; He MM Med Oncol; 2016 Nov; 33(11):122. PubMed ID: 27730526 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Rieger G; Koelzer VH; Dawson HE; Berger MD; Hädrich M; Inderbitzin D; Lugli A; Zlobec I Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]